Syndax Pharmaceuticals Inc
1T3
Company Profile
Business description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Contact
35 Gatehouse Drive
Building D, Floor 3
WalthamMA02451
USAT: +1 781 419-1400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
184
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,705.00 | 5.90 | 0.07% |
| CAC 40 | 7,217.86 | 17.25 | -0.24% |
| DAX 40 | 19,825.12 | 198.67 | 1.01% |
| Dow JONES (US) | 44,910.65 | 188.59 | 0.42% |
| FTSE 100 | 8,303.99 | 16.69 | 0.20% |
| HKSE | 19,550.29 | 126.68 | 0.65% |
| NASDAQ | 19,218.17 | 157.69 | 0.83% |
| Nikkei 225 | 38,513.02 | 304.99 | 0.80% |
| NZX 50 Index | 13,114.68 | 47.76 | 0.37% |
| S&P 500 | 6,032.38 | 33.64 | 0.56% |
| S&P/ASX 200 | 8,447.90 | 11.70 | 0.14% |
| SSE Composite Index | 3,363.98 | 37.53 | 1.13% |